Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19001363rdf:typepubmed:Citationlld:pubmed
pubmed-article:19001363lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C0020445lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C0439855lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C1883559lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:19001363lifeskim:mentionsumls-concept:C0205296lld:lifeskim
pubmed-article:19001363pubmed:issue2lld:pubmed
pubmed-article:19001363pubmed:dateCreated2009-1-5lld:pubmed
pubmed-article:19001363pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:abstractTextPCSK9 regulates low density lipoprotein receptor (LDLR) levels and consequently is a target for the prevention of atherosclerosis and coronary heart disease. Here we studied the interaction, of LDLR EGF(A/AB) repeats with PCSK9. We show that PCSK9 binds the EGF(AB) repeats in a pH-dependent manner. Although the PCSK9 C-terminal domain is not involved in LDLR binding, PCSK9 autocleavage is required. Moreover, we report the x-ray structure of the PCSK9DeltaC-EGF(AB) complex at neutral pH. Compared with the low pH PCSK9-EGF(A) structure, the new structure revealed rearrangement of the EGF(A) His-306 side chain and disruption of the salt bridge with PCSK9 Asp-374, thus suggesting the basis for enhanced interaction at low pH. In addition, the structure of PCSK9DeltaC bound to EGF(AB)(H306Y), a mutant associated with familial hypercholesterolemia (FH), reveals that the Tyr-306 side chain forms a hydrogen bond with PCSK9 Asp-374, thus mimicking His-306 in the low pH conformation. Consistently, Tyr-306 confers increased affinity for PCSK9. Importantly, we found that although the EGF(AB)(H306Y)-PCSK9 interaction is pH-independent, LDLR(H306Y) binds PCSK9 50-fold better at low pH, suggesting that factors other than His-306 contribute to the pH dependence of PCSK9-LDLR binding. Further, we determined the structures of EGF(AB) bound to PCSK9DeltaC containing the FH-associated D374Y and D374H mutations, revealing additional interactions with EGF(A) mediated by Tyr-374/His-374 and providing a rationale for their disease phenotypes. Finally, we report the inhibitory properties of EGF repeats in a cellular assay measuring LDL uptake.lld:pubmed
pubmed-article:19001363pubmed:languageenglld:pubmed
pubmed-article:19001363pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:citationSubsetIMlld:pubmed
pubmed-article:19001363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19001363pubmed:statusMEDLINElld:pubmed
pubmed-article:19001363pubmed:monthJanlld:pubmed
pubmed-article:19001363pubmed:issn0021-9258lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:LoHHlld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:SitlaniAyesha...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:SparrowCarl...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:TalamoFabioFlld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:FisherTimothy...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:CubbonRose...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:CummingsRicha...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:CarfíAndreaAlld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:OrsattiLauraLlld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:BottomleyMatt...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:Lo...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:SantoroJoseph...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:CirilloAgosti...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:RuggeriLionel...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:CalzettaAless...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:BaysarowichJe...lld:pubmed
pubmed-article:19001363pubmed:authorpubmed-author:NotoAlessiaAlld:pubmed
pubmed-article:19001363pubmed:issnTypePrintlld:pubmed
pubmed-article:19001363pubmed:day9lld:pubmed
pubmed-article:19001363pubmed:volume284lld:pubmed
pubmed-article:19001363pubmed:ownerNLMlld:pubmed
pubmed-article:19001363pubmed:authorsCompleteYlld:pubmed
pubmed-article:19001363pubmed:pagination1313-23lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:meshHeadingpubmed-meshheading:19001363...lld:pubmed
pubmed-article:19001363pubmed:year2009lld:pubmed
pubmed-article:19001363pubmed:articleTitleStructural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.lld:pubmed
pubmed-article:19001363pubmed:affiliationDepartment of Biochemistry, Istituto di Ricerca di Biologia Molecolare "P. Angeletti", Via Pontina Km 30.600, 00040 Pomezia (Rome), Italy. matthew_bottomley@merck.comlld:pubmed
pubmed-article:19001363pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:255738entrezgene:pubmedpubmed-article:19001363lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19001363lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19001363lld:pubmed